๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations

โœ Scribed by Ravin Agah; Hungyi Shau; Amitabha Mazumder


Publisher
Springer-Verlag
Year
1987
Tongue
English
Weight
933 KB
Volume
24
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

โœฆ Synopsis


Little is known regarding the effectors of lymphokine-activated killer activity. Lysosomotropic agents such as quinacrine can be used to positively sort for lysosome rich cells in natural killer (NK) cell populations. We therefore decided to use this agent to sort lymphokine-activated killer (LAK) cells to characterize their lysosomal content. We found that the positively sorted population contained all the LAK activity, i.e., lysis of NK-resistant tumor cells (B16 melanoma cell line), with the negatively sorted cells having no killing activity. Therefore separation of interleukin-2-incubated cells for LAK activity could be accomplished using sorting after quinacrine staining. The treatment of positively sorted LAK cell populations with L-leucine methyl ester, a lysosomotropic dye which inhibits killing by lysosome rich cells, caused abrogation of killing of the B16 tumor by the treated populations. Single cell conjugate assays were also done on these sorted cells, with positively sorted cells forming the highest and negatively sorted cells the lowest percent of conjugates. Our data therefore indicates the important role of lysosome rich cells in the LAK cell population in the murine system.


๐Ÿ“œ SIMILAR VOLUMES


Immunotherapy of cancer with lymphokines
โœ John W. Yarbro ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 996 KB

Our expanding knowledge of the immune system has provided a basis of rationality for immunotherapy . Some non-specific immunotherapy has achieved the status of standard treatment: interferon in hairy cell leukemia and chronic myelogenous leukemia, BCG in bladder cancer, and levamisole in colon cance

Technical aspects of lymphokine-activate
โœ C. S. Carter; S. F. Leitman; H. Cullis; L. M. Muul; K. Nason-Burchenal; S. A. Ro ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 655 KB

Adoptive immunotherapy is a novel approach to treating patients with cancer, utilizing as therapy a patient's own peripheral blood lymphocytes that have been activated by incubation with interleukin-2 (IL-2). These cells develop the ability to mediate tumor regression in vivo and are referred to as